Executives from International Stem Cell Corporation (OTCBB:ISCO), a
biotechnology company specializing in the research and development of
stem cell-based therapies, will be presenting advances made in its
research programs related to the use of immune-matched patient-specific
parthenogenetic stem cells for neurological applications and genetic
liver diseases at Cell Science 2011 in Philadelphia on November 29th.
Vice President Ruslan Semechkin, Ph.D., will open the conference and
discuss the latest trends in the use of stem cells to treat diseases of
the central nervous system. A follow-on presentation will demonstrate
that functional dopaminergic neurons can be successfully obtained from
human parthenogenetic stem cells. Alina Ostrowska, Ph.D., the Company's
Director of Translational Research, will present a new method of
obtaining highly-enriched cultures of hepatocyte-like cells from
pluripotent human stem cells.
Dr Semechkin comments, "I'm honored to be opening this conference and to
be debating the latest advances in stem cell therapies. ISCO will also
be presenting the most recent results from two of our most important
research programs, where we continue to further characterize our
parthenogenetic stem cell lines and their ability to form functioning
liver-like cell and functioning neuron-like cells."
ISCO uses unfertilized oocytes to create human parthenogenetic stem
cells, an approach that offers a number of distinct advantages over
other types of human pluripotent stem cells. Like human embryonic stem
cells (hESCs), hpSCs are pluripotent, i.e. they have the capacity to
become almost any cell type in the body, yet avoid ethical issues
associated with use or destruction of viable human embryos. Unlike
hESCs, hpSCs can be created in a form such that they can be
immunologically matched to millions of individuals. ISCO maintains the
world's largest collection of research-grade hpSC lines.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes
(eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of differing
genders, ages and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true stem
cell bank, UniStemCell™. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology, and cell-based skin care products
through its subsidiary Lifeline Skin Care. More information is available
at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, potential sales
growth and other opportunities for the company and its subsidiaries,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products and the management of
collaborations, regulatory approvals, need and ability to obtain future
capital, application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth C. Aldrich,
Co-Chairman
760-940-6383
kaldrich@intlstemcell.com
Or:
Dr.
Ruslan Semechkin, Vice President
760-940-6383
ras@intlstemcell.com
Or:
Lippert/Heilshorn
& Associates
Don Markley
310-691-7100
dmarkley@lhai.com